182 related articles for article (PubMed ID: 14625337)
1. Chronic graft-vs-host disease.
Bhushan V; Collins RH
JAMA; 2003 Nov; 290(19):2599-603. PubMed ID: 14625337
[No Abstract] [Full Text] [Related]
2. Ocular graft-versus-host disease: a review.
Shikari H; Antin JH; Dana R
Surv Ophthalmol; 2013; 58(3):233-51. PubMed ID: 23541042
[TBL] [Abstract][Full Text] [Related]
3. Malar rash in a stem cell transplant recipient.
Mansh M; Johnson W; Lai J
JAMA; 2014 Aug; 312(5):547-8. PubMed ID: 25096696
[No Abstract] [Full Text] [Related]
4. Prognostic factors identifiable at the time of onset of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.
Remberger M
Haematologica; 2005 Jul; 90(7):870. PubMed ID: 15996922
[No Abstract] [Full Text] [Related]
5. Stem Cell Transplantation in Aplastic Anaemia.
Nair V; Apte S
J Assoc Physicians India; 2015 Mar; 63(3 Suppl):21-5. PubMed ID: 26529863
[No Abstract] [Full Text] [Related]
6. Edema with hypoalbuminemia as a rare manifestation of chronic graft versus host disease after allogeneic hematopoietic cell transplant.
Hogan JJ; Loren AW; Denker MG; Mangan JK
Leuk Lymphoma; 2017 Aug; 58(8):2008-2010. PubMed ID: 27998198
[No Abstract] [Full Text] [Related]
7. Prophylaxis and management of graft-versus-host disease.
Ezzone S
Oncology (Williston Park); 2008 Oct; 22(11 Suppl Nurse Ed):45. PubMed ID: 19856580
[No Abstract] [Full Text] [Related]
8. Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation.
Martin PJ; McDonald GB; Sanders JE; Anasetti C; Appelbaum FR; Deeg HJ; Nash RA; Petersdorf EW; Hansen JA; Storb R
Biol Blood Marrow Transplant; 2004 May; 10(5):320-7. PubMed ID: 15111931
[TBL] [Abstract][Full Text] [Related]
9. [Management of late complications after allogeneic hematopoietic stem cell transplantation].
Kurosawa S; Fukuda T
Rinsho Ketsueki; 2013 Feb; 54(2):167-76. PubMed ID: 23470823
[No Abstract] [Full Text] [Related]
10. Clinical update on graft-versus-host disease in children.
Goddard DS; Horn BN; McCalmont TH; Cordoro KM
Semin Cutan Med Surg; 2010 Jun; 29(2):92-105. PubMed ID: 20579598
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-22 in the diagnosis of active chronic graft-versus-host disease in paediatric patients.
Tumino M; Serafin V; Accordi B; Spadini S; Forest C; Cortese G; Lissandron V; Marzollo A; Basso G; Messina C
Br J Haematol; 2015 Jan; 168(1):142-5. PubMed ID: 25098229
[No Abstract] [Full Text] [Related]
12. [Hyperacute graft versus host disease after allo-stem cell transplantation, analysis of 118 cases].
Huang X; Chen Y; Guo N; Ren H; Zhang Y; Xu L; Gao Z; Lu D
Zhonghua Yi Xue Za Zhi; 2002 Apr; 82(8):511-4. PubMed ID: 12133493
[TBL] [Abstract][Full Text] [Related]
13. Long-term control of extensive refractory chronic graft versus host disease in a multiple myeloma relapsing after allogeneic transplant. A case report.
Cocito F; Mangiacavalli S; Bernasconi P; Colombo AA; Caldera D; Cartia CS; Ganzetti M; Troletti D; Cazzola M; Corso A
Leuk Lymphoma; 2017 Nov; 58(11):2770-2771. PubMed ID: 28287281
[No Abstract] [Full Text] [Related]
14. Chronic graft-versus-host disease: clinical manifestation and therapy.
Ratanatharathorn V; Ayash L; Lazarus HM; Fu J; Uberti JP
Bone Marrow Transplant; 2001 Jul; 28(2):121-9. PubMed ID: 11509929
[TBL] [Abstract][Full Text] [Related]
15. Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome.
Skert C; Patriarca F; Sperotto A; Cerno M; Filì C; Zaja F; Stocchi R; Geromin A; Damiani D; Fanin R
Haematologica; 2006 Feb; 91(2):258-61. PubMed ID: 16461315
[TBL] [Abstract][Full Text] [Related]
16. Oral chronic graft-versus-host disease in Australia: clinical features and challenges in management.
Hull K; Kerridge I; Avery S; McCullough M; Ritchie D; Szer J
Intern Med J; 2015 Jul; 45(7):702-10. PubMed ID: 26134695
[TBL] [Abstract][Full Text] [Related]
17. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
[TBL] [Abstract][Full Text] [Related]
18. [Complications of hematopoietic stem cell transplantation: physiopathology and management. 2. Graft-versus-host disease (GVHD)].
Morishita Y
Nihon Naika Gakkai Zasshi; 1998 Aug; 87(8):1502-9. PubMed ID: 9780678
[No Abstract] [Full Text] [Related]
19. Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets.
Zeiser R; Blazar BR
N Engl J Med; 2017 Dec; 377(26):2565-2579. PubMed ID: 29281578
[No Abstract] [Full Text] [Related]
20. The safety and efficacy of acute graft-versus-host disease prophylaxis with a higher target blood concentration of cyclosporine around 500 ng/mL.
Machishima T; Kako S; Wada H; Yamasaki R; Ishihara Y; Kawamura K; Sakamoto K; Sato M; Ashizawa M; Terasako K; Kimura S; Kikuchi M; Nakasone H; Kanda J; Yamazaki R; Nishida J; Kanda Y
Clin Transplant; 2013; 27(5):749-56. PubMed ID: 24033855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
